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 أول ملف للجينات اخللوية للمرضى العمانيني املصابني
مبتالزمة خلل النسج النقوي
مقارنة مع بيانات من اسيا وافريقيا وامريكا الشمالية واجلنوبية
اأ�سانديرا موثابا اأوداياكومار، جنالء فواز، اأنيل باثاري، �ساكيلة اأ�رصف، حممد احلنيني، خليل الفار�سي، �سالم الكندي، مرت�سى اخلابوري
abstract: Clonal cytogenetic abnormalities have been reported among 30–80% of patients with myelodysplastic 
syndromes (MDS); however, 20–70% of patients with MDS show a normal karyotype that may nevertheless 
harbour a cryptic genetic alteration. Earlier reports have suggested that the distribution of specific chromosomal 
aberrations varies among Western and Asian countries, with geographical and ethnic differences in the frequency 
of specific chromosomal aberrations. This article compared the cytogenetic data of 36 adult Omani patients with 
MDS to previously reported data from other populations. Differences were noted between the percentages of 
clonal aberrations and the median age of Omani subjects at presentation in comparison to individuals of different 
ethnicities and from various geographical locations. To the best of the authors’ knowledge, this is the first report 
to describe the cytogenetic data of patients with MDS from Oman.
Keywords: Cytogenetic Abnormalities; Chromosomal Aberrations; Myelodysplastic Syndromes; Population 
Heterogeneity; Ethnic Groups; Oman.
امللخ�ص: توجد تقاريرعن ت�سوهات للجينات اخللوية بني %80-30 من املر�سى الذين يعانون من متالزمات خلل التن�سج النقوي ومع 
ذلك فاأن، %70-20 من املر�سى الذين يعانون من هذه املتالزمة تظهر لديهم النمط النووي العادي الذي قد يوؤوي تغيري وراثي خفي. وقد 
اأ�سارت تقارير �سابقة اإىل اأن هناك توزيع كرومو�سومي �ساذ حمدد يتفاوت بني البلدان الغربية واالآ�سيوية، مع وجود اختالفات جغرافية 
وعرقية يف تواتر االنحرافات ال�سبغية املحددة. وقد قارنت هذه املقالة بيانات الوراثة اخللوية ل 36 مري�سا عمانيا بالغني يعانون من 
متالزمة خلل الن�سج النقوي اإىل بيانات �سبق االإبالغ عنها من �سعوب اأخرى. وقد لوحظت فروق بني ن�سب االنحرافات الن�سيلية والعمر 
الو�سيط للمواطنني العمانيني عند بداية املر�ص مقارنة باأفراد من خمتلف االأعراق ومن خمتلف املناطق اجلغرافية. اإىل حد علم املوؤلفني، 
هذا هو اأول تقرير لو�سف البيانات اخللوية اجلينية للمر�سى الذين يعانون من متالزمة خلل الن�سج النقوي من عمان.
جماعات ال�سكاين؛  التجان�ص  عدم  النقوي؛  التن�سج  خلل  متالزمات  الكرومو�سومات؛  �سذوذ  املن�ساأ؛  خلوية  ت�سوهات  املفتاحية:   الكلمات 
عرقية؛ عمان.
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Myelodysplastic syndromes (mds) area group of clonal haematopoietic stem cell diseases characterised by cytopaenia, 
dysplasia in one or more of the major myeloid cell 
lines, ineffective haematopoiesis and an increased 
risk of developing acute myeloid leukaemia 
(AML).1 Cytogenetic and molecular abnormalities 
are key elements in the diagnosis of MDS. Clonal 
chromosomal abnormalities in MDS have been 
observed in 30–80% of patients, depending on the 
subtype and whether it is de novo or mutagen-
induced.2,3 For the other 20–70% of MDS patients with 
normal karyotypes, there is substantial evidence for the 
presence of submicroscopic alterations—such as point 
mutations, microdeletions, microamplifications, epi- 
genetic changes or copy number neutral loss of 
information—which may form the genetic basis of the 
disease.4–6 The percentage of clonal abnormalities in 
the literature varies between 23–78%.7–9
Over time, MDS has been increasingly recognised 
as a cause of bone marrow failure; however, the precise 
incidence of de novo MDS is unknown.10 Jacobs et al. 
have suggested that the distribution of specific 
chromosomal aberrations in MDS varies between 
Western and Asian countries.11 Another report also 
indicated geographical and ethnic differences in the 
frequency of specific chromosomal aberrations.12 
The incidence of chromosomal abnormalities 
Achandira M. Udayakumar, Nagla Fawaz, Anil Pathare, Shakila Asraf, Mohammed Al-Huneini, 
Khalil Al-Farsi, Salam Al-Kindi and Murtadha Al-Khabouri
Special Contribution | e287
in Indian population has been reported to vary 
from 37.5–88%.13 In addition, the frequency of 
chromosomal abnormalities varies between 37–50% 
in China, Thailand, Hong Kong and Japan.13,14 Complex 
aberrations have been more frequently observed in 
Indian patients as compared to those from other Asian 
countries.13 
As such, ethnic and/or geographical differences 
could be heterogeneous and contribute to clinical, 
cytogenetic or molecular events leading to MDS. 
Available reports on the incidence of MDS mostly 
originate from European countries, although major 
studies have been conducted in Japan.15–22 To the 
best of the authors’ knowledge, this is the first report 
detailing the cytogenetic profile of Omani patients 
with MDS. In order to analyse ethno-geographical 
differences in the pathogenesis of MDS, the current 
article aimed to compare the cytogenetic findings of 
Omani patients with de novo MDS with available data 
from Europe, North and South America, Africa and 
other Asian countries.
Methods
Data were collected from all patients with MDS 
presenting between 2006–2013 to the Department 
of Haematology at the Sultan Qaboos University 
Hospital (SQUH), a tertiary care centre in Muscat, 
Oman. A diagnosis of MDS was made as per the 
criteria of the World Health Organization (WHO).23 
Patients who did not fulfill the WHO criteria were 
excluded. All eligible subjects subsequently had their 
peripheral blood count recorded. In addition, bone 
marrow samples were obtained prior to the initiation 
of any therapy.
Cytogenetic analysis of the bone marrow 
samples was performed using GTG banding, with 
karyotypes reported according to the International 
System for Human Cytogenomic Nomenclature.24 At 
least 20 metaphases were karyotyped and analysed 
from 24- and 48-hour bone marrow cultures. Clonal 
Table 1: Characteristics of Omani patients with 
myelodysplastic syndromes presenting to the Sultan 




Female  18 (50.0)
Age in years




Median haemoglobin in g/dL (range) 8.7 (6.2–14.9)
Median ANC in x109/L (range) 1.3 (0.1–31.5)
Median platelet count in x109/L (range) 77 (5–591)
Cytopaenia
None 1 (2.8)
Single lineage 7 (19.4)
Bilineage 15 (41.7)
Trilineage 13 (36.1)





Supportive only 29 (80.6)
Chemotherapy 1 (2.8)
















ANC = absolute neutrophil count; MDS = myelodysplastic syndromes; 
RA = refractory anaemia; RARS = refractory anaemia with ringed 
sideroblasts; RCMD = refractory cytopaenia with multilineage 
dysplasia; RAEB = refractory anaemia with excess blasts; U = 
unclassified; AML = acute myeloid leukaemia.
*Defined as per the criteria of the World Health Organization.23
†Including one case of MDS associated with an isolated del(5q) 
abnormality.
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abnormalities were defined as two or more cells with 
the same whole chromosome gain/chromosome 
rearrangement or three or more cells with the same 
chromosome loss. A complex karyotype was defined 
as three or more cytogenetic abnormalities. 
Ethical approval for this research was received 
from the Research & Ethics Committee of the College 
of Medicine & Health Sciences, Sultan Qaboos 
University (MREC #896). 
Table 2: Age/gender distribution across subtypes of Omani patients with myelodysplastic syndromes presenting to 
the Sultan Qaboos University Hospital, Muscat, Oman (N = 36)
MDS subtype* n (%)
Total Age in years Gender
0–20 21–40 41–60 >60 Male Female
RA 8 (22.2) 0 (0.0) 0 (0.0) 2 (5.4) 6 (16.7) 3 (8.3) 5 (13.9)
RARS 3 (8.3) 0 (0.0) 0 (0.0) 1 (2.8) 2 (5.6) 3 (8.3) 0 (0.0)
RCMD 11 (30.6) 0 (0.0) 1 (2.7) 4 (11.1) 6 (16.7) 5 (13.9) 6 (16.7)
RAEB 6 (16.7) 1 (2.8) 0 (0.0) 2 (5.6) 3 (8.3) 3 (8.3) 3 (8.3)
MDS-U 8 (22.2) 0 (0.0) 1 (2.7) 1 (2.8) 6 (16.7) 4 (11.1) 4 (11.1)
Total 36 (100.0) 1 (2.8) 2 (5.6) 10 (27.8) 23 (63.9) 18 (50.0) 18 (50.0)
MDS = myelodysplastic syndromes; RA = refractory anaemia; RARS = refractory anaemia with ringed sideroblasts; RCMD = refractory cytopaenia 
with multilineage dysplasia; RAEB = refractory anaemia with excess blasts; U = unclassified.
*Defined as per the criteria of the World Health Organization.23
Table 3: Cytogenetic prognosis of Omani patients with myelodysplastic syndromes presenting to the Sultan Qaboos 
University Hospital, Muscat, Oman (N = 36)




RA RARS RCMD RAEB MDS-U‡
Very good -Y 1 (2.8) - - - - 1 (2.8)
Good Normal 23 (63.9) 6 (16.7) 2 (5.6) 8 (22.2) 4 (11.1) 3 (8.3)
del(5q) 1 (2.8) 1 (2.7) - - - -
del(12p) 0 (0.0) - - - - -
del(20q) 0 (0.0) - - - - -
Intermediate (all single/double 
abnormalities) 
del(7q) 0 (0.0) - - - - -
+8 2 (5.6) 1 (2.8) - - 1 (2.8) 1 (2.8)
i(17)(q10) 1 (2.8) - - - - 1 (2.8)
+19 0 (0.0) - - - - -
+21 1 (2.8) 1 (2.8) - - - -
Poor (including double 
abnormalities)
inv(3) 0 (0.0) - - - - -
t(3q) 0 (0.0) - - - - -
del(3q) 0 (0.0) - - - - -
Very poor Complex 1 (2.8) - - - 1 (2.8) -
MDS = myelodysplastic syndromes; RA = refractory anaemia; RARS = refractory anaemia with ringed sideroblasts; RCMD = refractory cytopaenia 
with multilineage dysplasia; RAEB = refractory anaemia with excess blasts; U = unclassified.
*As per the Revised International Prognostic Scoring System.25
†The total dataset does not add up to 36 as some patients may have had more than one abnormality.
‡Including two cases of MDS-U with a del(18p) abnormality and one other abnormality. 
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Cytogenetic and Patient Data 
from Oman
A total of 36 Omani patients with MDS were 
successfully karyotyped. Of these, eight patients had 
refractory anaemia (RA; 22.2%), three had RA with 
ringed siderolasts (8.3%), 11 had refractory cytopaenia 
with multilineage dysplasia (30.6%), six had RA with 
excess blasts (16.7%) and eight had unclassified MDS 
(22.2%). One of the patients with RA with ringed 
siderolasts had MDS associated with an isolated 
del(5q) abnormality. Cytopaenia with bilineage was 
observed in 15 patients (41.7%), while cytopaenia with 
trilineage was seen in 13 patients (36.1%). Most of 
the patients (75.0%) had <5% bone marrow blasts. A 
total of 29 patients received supportive therapy only 
(80.6%). Seven patients had AML transformation 
(19.4%). The mortality rate was 25.0%. There was an 
equal number of male and female patients and the 
majority of the patients were over 60 years old (63.9%) 
[Table 1]. The median follow-up period was 28 months 
(range: 3–70 months). Table 2 shows the distribution 
of MDS subtypes according to age and gender.
Overall, 26 patients (72.2%) had normal karyo-
types which indicated a good prognosis according to 
the Revised International Prognostic Scoring System 
(IPSS-R) [Table 3].25 One patient had a normal 
variant and another had a non-clonal abnormality. 
Eight patients had abnormal karyotypes (22.2%), of 
which two patients had clones which had trisomy 8 
and one patient each had trisomy 21, a del(5)(q15q31) 
abnormality, a del(11)(q23) abnormality, an i(17)(q10) 
abnormality, a del(18)(p11) abnormality and an absent 
Y chromosome [Table 4]. Six of these eight patients 
also showed normal clones along with abnormal 
clones. 
Comparison of Omani Data 
with Other Populations
The characteristics of Omani patients with MDS were 
compared to those previously reported from other 
populations [Table 5].3,7,11,13,15,16,22,26–33 The median age 
of patients with MDS in Oman (65 years old) was lower 
than that reported from Europe (65–74 years old) 
but was higher compared to other Asian countries 
(50–60 years old).10,13,15,17,19–22,26,28,31 The median age of 
the patients in Tunisia was 60 years old.22 Brazilian 
patients had the youngest median age (29 years old).27 
Among Omani patients, the male-to-female ratio 
was 1:1, which was in accordance with a sample from 
Thailand and close to ratios reported from Brazil (1.2:1) 
and Germany (1.3:1);3,26,27 however, this finding was 
contrary to many other Asian countries and certain 
European, North American and African countries 
in which males outnumbered females.7,11,13,15,22,28,30,31 
Further research is needed to determine a possible 
cause for this gender difference between populations. 
The majority of Omani patients showed normal 
karyotypes (62.2%) and were believed to have a 
good prognosis according to IPSS-R classifications.25 
Only published data on the frequency of abnormal 
karyotypes from Japan (23.9%) and China (37.1%) 
were close to the data from Oman.16,28 Chromosomal 
abnormalities such as i(17q), trisomy 21 and the 
absence of the Y chromosome were seen in one each 
of the Omani patients (2.8% each). Studies from 
Germany, Japan and Argentina also reported patients 
with loss of the Y chromosome (7.0%, 1.1% and 2.7%, 
respectively);3,15,29 however, this abnormality was not 
observed among patients from Thailand, Switzerland 
or Brazil.7,26,27 Similarly, trisomy 21 was not observed 
Table 4: Abnormal karyotypes among Omani patients with myelodysplastic syndromes presenting to the Sultan 
Qaboos University Hospital, Muscat, Oman (N = 36)
Patient Age/gender MDS subtype* Karyotype Survival in 
months
1 69/M MDS-U 45,X,-Y[17]/46,XY[3] 18
2 67/F MDS-U 46,XX,del(18)(p11)[20] 5
3 67/F RAEB 46,XX,add(1)(q42) del(13)(q31)[13]/46,XX[7] 16
4 78/F RCUD 47,XX,+21[17]/46,XX[1] 4
5 68/F MDS-U 47,XX,+8[9]/46,XX[11] 7
6 64/F RA 46,XX,del(5)(q15q31),del(11)(q23)[8]/46,XX[6] 5
7 58/F RAEB 51,XX,+1,+8,+10,+i(11)(q10),+13[18] 3
8 67/M MDS-U 46,XY,i(17)(q10)[4]/46,XY[27] 15
MDS = myelodysplastic syndromes; M = male; U = unclassified; F = female; RAEB = refractory anaemia with excess blasts; RCUD = refractory 
cytopaenia with unilineage dysplasia; RA = refractory anaemia.
*Defined as per the criteria of the World Health Organization.23
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in Thailand or India.13,26 The USA had the lowest per-
centage of AML transformation (2.8%), followed by 
Korea (16.8%) and Oman (19.4%).31
The overall percentage of abnormal karyotypes 
was lower among Omanis compared to other 
populations (22.2% versus 23.9–68.8%), although this 
may be due to the low number of patients included 
in the Omani sample.3,7,11,13,15,16,22,26–33 The highest 
percentage of patients with abnormal karyotypes was 
reported from Brazil.27 The frequency of cytogenetic 
abnormalities according to MDS subtype was 
found to be different among Omani patients when 
compared to other populations, with most Omani 
patients having normal karyotypes and thus a good 
prognosis.3,7,11,13,15,16,22,26–33
The current research sought to compare the 
cytogenetic characteristics of Omani patients with 
MDS to those reported among other geographic/
ethnic populations. A review of the literature revealed 
that this dataset constitutes the first report from an 
ethnic Omani population. However, verification of 
the findings of this research is needed with a larger 
sample. As the native Omani population is relatively 
small, numbering approximately 2.35 million in 2015, 
the number of patients with MDS presenting to SQUH 
was hence limited and the sample size too small to 
draw statistically significant conclusions.34 As such, 
it is recommended that the sample size be increased 
in future studies. Socioeconomic characteristics and 
access to the healthcare system may also contribute 
to MDS awareness and detection rates within a 
given population. The referral of suspected patients 
from rural healthcare centres to tertiary hospitals 
for cytogenetic testing could also increase the 
detection/confirmation of MDS markers for better 
characterisation. 
Conclusion
To the best of the authors’ knowledge, this report is 
the first from an Omani population detailing the 
cytogenetic characteristics of patients with MDS. 
These data may serve as a basis for further research in 
Oman and a comparison with other populations. 
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